Safety and Immunogenicity of Pertussis Vaccine Immunization during Pregnancy: A Meta-Analysis of Randomized Clinical Trials

Table 1

Description of the characteristics of the included studies.

Source	Country	Type of vaccines during pregnancy (experimental group/control group)	Study period	Study design	Registration no.	Gestational age in weeks of vaccination	Participants no. (experimental group/control group)
Barug et al. [26]	Netherlands	Tdap/---	January 2014–March 2016	RCT, open-label	EudraCT 2012-004006-9/NTR number NTR4314	30–32 weeks	58/60
Perrett et al. [30]	Australia, Canada, Czech Republic, Finland, Italy and Spain	Tdap/placebo	October 2015–October 2017	RCT, observer-blind	NCT02377349	27–36 weeks	341/346
Munoz et al. [27]	The United States	Tdap/placebo	October 2008–May 2012	RCT, double-blind	NCT00707148	30–32 weeks	33/15
Hoang et al. [28]	Vietnam	Tdap/TT	NA	RCT	NA	18–36 weeks	52/51
Villarreal Pérez et al. [29]	Mexico	Tdap/placebo	September 2011–August 2014	RCT, double-blind	NCT01445743	30–32 weeks	90/81
Halperin et al. [31]	Canada	Tdap/Td	November 2007–June 2011	RCT, observer-blind	NCT00553228	≥30 weeks	135/138

Note. “---” = not received Tdap or placebo during pregnancy. TT = tetanus toxoid. Td = tetanus and diphtheria toxoids. NA = not applicable.